文献速递肝病

药理学抑制表皮生长因子受体可抑制快餐饮食小鼠模型中的非酒精性脂肪性肝病

Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model.
PubMed 文献 · Hepatology · 2019-06-19

本研究在C57BL6/J小鼠快餐饮食(FFD)模型中,用EGFR抑制剂卡奈替尼(canertinib)干预,发现EGFR抑制可完全预防2个月FFD诱导的脂肪变性和肝损伤,并显著逆转5个月FFD已形成的脂肪变性、肝损伤和纤维化,改善糖耐量。机制涉及EGFR调控脂代谢基因及PPARγ、SREBF1等转录因子,且该效应不由MET受体共享。

要点

  • 卡奈替尼抑制EGFR可完全预防2个月快餐饮食诱导的小鼠脂肪变性和肝损伤。
  • 5个月快餐饮食后给予卡奈替尼5周,可显著减轻脂肪变性、肝损伤和纤维化并改善糖耐量。
  • EGFR抑制调控脂代谢基因及PPARγ、SREBF1等转录因子,并抑制AKT信号。

核心结论

  • 本研究揭示了EGFR在非酒精性脂肪性肝病(NAFLD)中的作用,并提示EGFR抑制可能作为NAFLD的治疗策略。

研究设计与样本

  • 研究使用C57BL6/J小鼠,分别喂食普通饲料或快餐饮食(FFD),并联合或不联合EGFR抑制剂卡奈替尼(canertinib)干预。
  • 预防实验:小鼠喂食FFD 2个月,同步给予或不给予卡奈替尼。
  • 逆转实验:小鼠喂食FFD 5个月,在最后5周给予或不给予卡奈替尼。
  • 机制实验包括微阵列分析、染色质免疫沉淀分析,以及利用MET敲除小鼠比较MET受体作用。

主要发现

  • EGFR抑制完全预防了2个月FFD模型中脂肪变性和肝损伤的发生。
  • 在5个月FFD模型中,最后5周卡奈替尼治疗显著减轻脂肪变性、肝损伤和纤维化,并改善糖耐量。
  • 微阵列分析显示,FFD改变的基因中约40%在EGFR抑制后表达差异,提示可能受EGFR调控。
  • EGFR抑制调节了FFD disrupt的脂代谢相关基因和酶,以及PPARγ、SREBF1、碳水化合物反应元件结合蛋白和肝细胞核因子4α等转录因子。
  • 染色质免疫沉淀分析显示,EGFR抑制大幅减少PPARγ与脂肪酸合酶、硬脂酰辅酶A去饱和酶1和perilipin 2等关键脂代谢基因的结合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epidermal growth factor receptor (EGFR) is a critical regulator of hepatocyte proliferation and liver regeneration. Our recent work indicated that EGFR can also regulate lipid metabolism during liver regeneration after partial hepatectomy. Based on these findings, we investigated the role of EGFR in a mouse model of nonalcoholic fatty liver disease (NAFLD) using a pharmacological inhibition strategy. C57BL6/J mice were fed a chow diet or a fast-food diet (FFD) with or without EGFR inhibitor (canertinib) for 2 months. EGFR inhibition completely prevented development of steatosis and liver injury in this model. In order to study if EGFR inhibition can reverse NAFLD progression, mice were fed the FFD for 5 months, with or without canertinib treatment for the last 5 weeks of the study. EGFR inhibition remarkably decreased steatosis, liver injury, and fibrosis and improved glucose tolerance. Microarray analysis revealed that ~40% of genes altered by the FFD were differentially expressed after EGFR inhibition and, thus, are potentially regulated by EGFR. Several genes and enzymes related to lipid metabolism (particularly fatty acid synthesis and lipolysis), which were disrupted by the FFD, were found to be modulated by EGFR. Several crucial transcription factors that play a central role in regulating these lipid metabolism genes during NAFLD, including peroxisome proliferator-activated receptor gamma (PPARγ), sterol regulatory element-binding transcription factor 1 (SREBF1), carbohydrate-responsive element-binding protein, and hepatocyte nuclear factor 4 alpha, were also found to be modulated by EGFR. In fact, chromatin immunoprecipitation analysis revealed that PPARγ binding to several crucial lipid metabolism genes (fatty acid synthase, stearoyl-coenzyme A desaturase 1, and perilipin 2) was drastically reduced by EGFR inhibition. Further upstream, EGFR inhibition suppressed AKT signaling, which is known to control these transcription factors, including PPARγ and SREBF1, in NAFLD models. Lastly, the effect of EGFR in FFD-induced fatty-liver phenotype was not shared by receptor tyrosine kinase MET, investigated using MET knockout mice. Conclusion: Our study revealed a role of EGFR in NAFLD and the potential of EGFR inhibition as a treatment strategy for NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Bhushan B, Banerjee S, Paranjpe S, et al. Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model. Hepatology. 2019. PMID: 31063640. doi:10.1002/hep.30696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。